---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014641"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:22:08.181887+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q3 core revenue up 23% YoY to $8.1M; net loss $11.6M; guidance raised

## Summary
- Total Q3 revenue $8.2M (+2% YoY); core business revenue $8.1M (+23% YoY) driven by cell therapy growth of 39%.
- Net loss of $11.6M vs $11.3M in Q3 2023; EBITDA loss $13.0M; stock-based comp $3.4M.
- Signed 6 new SPL clients YTD, including Kamau, Legend Biotech, Be Bio; total SPL partners now 29.
- Full-year core revenue guidance raised to at least 5% growth; SPL program revenue affirmed at ~$6M.
- Cash and investments $196.6M at Sep 30; expects to end 2024 with ~$185M; evaluating potential AIM listing cancellation.

## SEC filing metadata
- accession: 0001558370-24-014641
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837024014641/0001558370-24-014641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837024014641/mxct-20241106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014641
- JSON: https://secwatch.observer/filing/0001558370-24-014641.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.